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Abstract
Background: The MYCN gene is transcribed into two major mRNAs: one full-length (MYCN) and
one exon 1b-spliced (MYCNΔ1b) mRNA. But nothing is known about their respective ability to
translate the MYCN protein.
Methods: Plasmids were prepared to enable translation from the upstream (uORF) and major
ORF of the two MYCN transcripts. Translation was studied after transfection in neuroblastoma SH-
EP cell line. Impact of the upstream AUG on translation was evaluated after directed mutagenesis.
Functional study with the two MYCN mRNAs was conducted by a cell viability assay. Existence of
a new protein encoded by the MYCNΔ1b uORF was explored by designing a rabbit polyclonal
antibody against a specific epitope of this protein.
Results: Both are translated, but higher levels of protein were seen with MYCNΔ1b mRNA. An
upstream ORF was shown to have positive cis-regulatory activity on translation from MYCN but
not from MYCNΔ1b mRNA. In transfected SH-EP neuroblastoma cells, high MYCN dosage obtained
with MYCNΔ1b mRNA translation induces an antiapoptotic effect after serum deprivation that was
not observed with low MYCN expression obtained with MYCN mRNA. Here, we showed that
MYCNOT: MYCN Overlap Transcript, a new protein of unknown function is translated from the
upstream AUG of MYCNΔ1b mRNA.
Conclusions: Existence of upstream ORF in MYCN transcripts leads to a new level of MYCN
regulation. The resulting MYCN dosage has a weak but significant anti-apoptotic activity after
intrinsic apoptosis induction.
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Background
The MYCN gene, located in 2p23-24 [1] has been demon-
strated to be composed of three exons (Fig. 1): exon 1a/b,
exon 2 and exon 3, and the coding sequence for MYCN
has been mapped to exons 2 and 3 [2]. Several transcripts
have been described; one full length: MYCN mRNA and
two alternatively spliced mRNAs; one containing exons
1a, 2 and 3: MYCNΔ1b mRNA [2,3] and the other contain-
ing exons 1a and 3: MYCNΔ1b,2 mRNA [4]. Only MYCN
and MYCNΔ1b transcripts might translate the MYCN pro-
tein. It was previously hypothesized but neither proven
nor explored that an upstream AUG (uAUG) located in
+1894 (according to GenBank: Y00664) of MYCNΔ1b
mRNA might translate a protein (GenBank: AAG40001.1)
[5]. Moreover, as proposed by van Bokhoven et al,
MYCNΔ1b,2 mRNA could be able to initiate translation of a
new protein (ΔMYCN) from the same uAUG [4].
The existence of upstream open reading frames (uORFs)
has been described in detail for many genes, and these
uORFs could represent as much as half of the whole tran-
scriptome [6,7]. Most studies have shown a negative cis-
regulatory function of the major ORF [6-8].
MYCN, a basic helix-loop-helix transcription factor that
belongs to the MYC family, was initially identified as a
gene amplified in neuroblastoma, the most frequent pae-
diatric extra-cranial solid tumour [9]. Numerous experi-
ments have demonstrated its importance during
ontogenesis. In the developing mouse embryo, MYCN is
required for normal organogenesis of the heart, neural
tube, spinal ganglia, visceral arches, liver, stomach, limb
buds and eyes [10]. More precisely, MYCN is essential to
maintain a population of undifferentiated and proliferat-
ing progenitor cells in the brain [11] and the distal lung
epithelium [12] of mouse embryos. MYCN is also able, in
chick embryos, to initiate the ventral migration of cells
from the neural crest to the sympathetic ganglia and to
induce their differentiation into neurons [13].
The overexpression of MYCN in the presence of deregu-
lated H-ras has been shown to contribute to the neoplastic
transformation of rat embryo cells, suggesting an onco-
genic role of MYCN [14]. This oncogenic role was later
confirmed using MYCN-transgenic mice: targeted expres-
sion of MYCN to neural crest-derived cells under the con-
trol of the Tyrosine Hydroxylase promoter leads to the
development of neuroblastoma-like tumours in all
homozygous mice [15].
The amplification and overexpression of MYCN primarily
found in 25% of neuroblastomas are associated with
advanced tumour stage, tumour progression and poor
outcome [16]. MYCN can also be overexpressed in other
The MYCN oncogene and encoded proteins Figure 1
The MYCN oncogene and encoded proteins. a) Annotated sequence of MYCN according to Genbank Y00664. b) Alter-
native splicing and putative proteins encoded by MYCN. c) MYCNOT sequence. Bold aminoacids: shared homology with the 
putative ΔMYCN [4]. Underlined aminoacids: selected epitope for polyclonal antibody production in rabbit.BMC Cancer 2009, 9:445 http://www.biomedcentral.com/1471-2407/9/445
Page 3 of 7
(page number not for citation purposes)
tumours including medulloblastoma, retinoblastoma,
small cell lung cancer, glioblastoma and other embryonal
tumours [17] suggesting the implication of MYCN dosage
in cancer development and aggressive expressivity. In sin-
gle copy MYCN (SCN) neuroblastoma cell lines, MYCN
has also been demonstrated to enhance proliferation after
bFGF administration [18]. Contrariwise, the protein
exhibits pro-apoptotic properties in particular conditions
such as drug-triggered apoptosis [19,20] or induction of
the death receptor machinery by TRAIL [21].
Thus, MYCN protein exhibits dual properties in prolifera-
tion and apoptosis, both in physiological and in patho-
logical conditions.
In the present work, we evidenced a link between MYCN
transcription and the level of MYCN translation. In vitro
translation of the two coding mRNAs led to different lev-
els of MYCN expression, with MYCNΔ1b mRNA being the
most efficient. Their translation was differently regulated
by an uORF located in the long 5' untranslated region of
exon 1a/b. Moreover, we observed that the uORF of
MYCN mRNA was able to up-regulate MYCN translation,
whereas the uORF of MYCNΔ1b  mRNA was not. Our
results demonstrated a MYCN dosage effect in SH-EP cells
in which high amounts of MYCN were anti-apoptotic
after serum deprivation, compared to low levels or
absence of MYCN. Finally, the uORF of MYCNΔ1b mRNA
directed the translation of a new protein of unknown
function, MYCNOT.
Methods
Cell culture
SH-EP cell line (an epithelial substrate-adherent
Schwann-like clone issued from SK-N-SH neuroblastoma
cell line[22] that do not express MYCN protein was cul-
tured in RMPI 1640 (Sigma) supplemented with 10% foe-
tal calf serum (GIBCO), penicillin G (200 IU/mL;
GIBCO), streptomycin sulphate (200 μG/mL; GIBCO)
and L-glutamine (2 mM; GIBCO) at 37°C in an atmos-
phere containing 5% CO2.
Plasmids preparation
Plasmid preparations were based on the Invitrogen Gate-
way® technology. Inserts were prepared from human foe-
tal brain mRNAs (Clontech) with a forward primer
specific to the very beginning of exon 1a/b at +1865
(according to Genbank Y00664) flanked with an attB1
sequence. Depending on the desired construct, three
reverse primers extended with an attB2 sequence were
designed. The first one, for p-uORF/MYCN was compli-
mentary to the sequence of the penultimate nucleotides of
the first stop codon of the MYCN mRNA in frame with the
uAUG codon located at +1894. The second one, for p-
uORF/MYCNΔ1b, was complimentary to the sequence of
the penultimate nucleotides of the first stop codon of
MYCNΔ1b mRNA in frame with the same uAUG codon.
The third reverse primer, for p-MYCN and p-MYCNΔ1b, was
complementary to the sequence of the penultimate nucle-
otides of the MYCN stop codon in exon 3. DNAs ampli-
fied from MYCN and MYCNΔ1b mRNAs were inserted into
pDEST40 according to Invitrogen Gateway® protocols with
a C-terminal V5 epitope tag for visualizing protein trans-
lation.
The plasmids p-MYCNmut  and  p-MYCNΔ1b,  mut  were
obtained respectively from p-MYCN and p-MYCNΔ1b by
mutation of the upstream AUG located in +1894 into an
AUC using the Quickchange® Site-Directed Mutagenesis
kit (Stratagene).
Cell transfection
For translational studies, three independant experiments
were conducted in duplicate: SH-EP cells were sowed at a
density of 200000 cells in 6-wells plates and transfected
the next day with 3.6 μg of purified MYCN-derived plas-
mids or control pcDNA/GW-40/lacZ (Invitrogen), 0.4 μg
p-EGFP (Clontech) and 8 μL Lipofectamine 2000 (Invitro-
gen). Cells were harvested 24 hours after transfection.
For apoptosis experiments, three independent experi-
ments were conducted in quadruplate: SH-EP cells were
sowed at a density of 200000 cells in 6-wells plates and
cultured in RMPI 1640 supplemented with 0.5% foetal
calf serum, penicillin G (200 IU/mL), streptomycin sul-
phate (200 μG/mL) and L-glutamine (2 mM) for 48 hours
at 37°C in an atmosphere containing 5% CO2, then trans-
fected with 3.6 μg of p-MYCN, p-MYCNΔ1b or pcDNA/GW-
40/lacZ, 0.4 μg pEGFP and 8 μL Lipofectamine 2000. After
transfection, cells were cultured for an additional day in
the same medium supplemented with 10% foetal calf
serum.
Western blotting
Proteins (40 μg) from cell lysates or from a human foetal
and adult brain (protein Medley™; BD Biosciences) were
separated by SDS-PAGE and transferred to 0.2 μm-nitro-
cellulose membranes (Biorad). Protein levels were deter-
mined using:
- a mouse anti-V5 epitope monoclonal antibody
(1:5000, Invitrogen),
- a mouse anti-human β-ACTIN monoclonal antibody
(1:200000, Sigma),
- a rabbit anti-NGAERSPQSPAGRRA [anti-MYCNOT]
peptide polyclonal antibody (1:100, Eurogentec),
whose specificity was checked by manufacturer
- a mouse anti-human MYCN monoclonal antibody,
clone B8.4.B (1:1000, BD Pharmingen).BMC Cancer 2009, 9:445 http://www.biomedcentral.com/1471-2407/9/445
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Primary antibodies were detected using goat anti-mouse
(1:10000, Sigma) or anti-rabbit (1:3000, Sigma) horse-
radish peroxidase-conjugated secondary antibodies, and
visualized using an enhanced chemiluminescence HRP
substrate (Millipore).
Cell viability assay
Cell viability was measured with Uptiblue viable cell
counting reagent (Uptima) before serum deprivation and
one day after transfection: cells were incubated for two
hours after addition of 10% Uptiblue, fluorescence was
measured with 530 nm excitation wavelength and 590
nm emission wavelength.
A one-sided student-t test was performed on the serum
deprivation-induced apoptosis calculated as the fluores-
cence difference between the two measures.
Results
MYCN and MYCN 1b mRNAs are differently translated
Since alternative splicing of exon 1b affects a potential
upstream open reading frame (uORF), we speculated that
it could influence the translation of MYCN protein. Vec-
tors p-MYCN and p-MYCNΔ1b were prepared to allow the
translation of MYCN respectively from these two mRNAs.
In SH-EP neuroblastoma cells, transfection assays fol-
lowed by Western blot showed no MYCN expression in
presence of the control plasmid (pcDNA/GW40/lacZ),
weak but detectable translation from p-MYCN, whereas a
very high amount of protein was obtained with p-
MYCNΔ1b (Fig. 2a). The observed differences are not a sim-
ple consequence of experimental variations in either
transfection efficacy, because cotransfection of p-EGFP
induced no difference in the number of GFP-expressing
cells between experiments (data not shown), or RNA tran-
scription or stability, because semi quantitative RT-PCR
analysis showed no difference in the levels of MYCN and
MYCNΔ1b  transcripts brought by plasmids (data not
shown). Upstream ORF is usually known for cis-acting
inhibitory effect on translation of the major protein. To
test this hypothesis, the upstream AUG was mutated to
AUC to produce p-MYCNmut and p-MYCNΔ1b, mut vectors.
MYCN levels in SH-EP cells clearly diminished when it
was translated from MYCN  transcripts, but not from
MYCNΔ1b transcripts (Fig. 2b).
High MYCN dosage enhances cell viability
To explore the effect of MYCN dosage, SH-EP cells were
subjected to apoptosis by 48-hour serum deprivation,
then transfected with either control pcDNA/GW40/lacZ, p-
MYCN, or p-MYCNΔ1b plasmids. As shown in Table 1,
when SH-EP cells did not express (pcDNA/GW-40/lacZ
transfected cells) or expressed low amount (p-MYCN
transfected cells) of MYCN protein, serum deprivation
induced similar cell loss (respectively 35.56% +/- 6.68%
and 34.94 +/- 7.19%; p = 0.60). When SH-EP cells
expressed high levels (p-MYCNΔ1b  transfected cells) of
MYCN protein, apoptosis (26.72% +/- 8.09%) was signif-
icantly (p = 0.01 and p = 0.02 respectively compared to
previous conditions) reduced by one third.
MYCNOT is translated from a upstream AUG of MYCN 1b 
mRNA
We speculated that uAUG, located in +1894 (according to
GenBank: Y00664, may initiate the translation and we
assessed the importance of alternative splicing of exon 1b.
In SH-EP cells, the transfection of p-uORF/MYCNΔ1b,
Exon 1b-splicing, uAUG and MYCN translation Figure 2
Exon 1b-splicing, uAUG and MYCN translation. a) 
Western blot analysis of 40 μg SH-EP neuroblastoma cells 
transfected with either control pcDNA/GW40/lacZ (lane 1), p-
MYCN (lane 2) or p-MYCNΔ1b (lane 3). Results obtained with -
upper panel: a monoclonal antibody against MYCN (1:1000) 
and -lower panel: a monoclonal antibody against β-Actin 
(1:10000). b) Western blot analysis of 40 μg SH-EP cells 
transfected with either p-MYCN (lane 1), p-MYCNmut (lane 2), 
p-MYCNΔ1b (lane 3) or p-MYCNΔ1b, mut (lane 4). Results 
obtained with -upper panel: the anti-MYCN antibody 
(1:1000) and -lower panel: the anti β-Actin antibody 
(1:10000).
Table 1: MYCN dose-dependant anti-apoptotic effect after 
serum deprivation.
Transfected plasmids Cell viability (%)
pcDNA/GW-40/lacZ 64.44 +/- 6.68
pMYCN 65.06 +/- 7.19a
pMYCNΔ1b 73.27 +/- 8.09b,c
MYCN dose-dependant enhanced SH-EP 
viability after serum deprivation measured 
with Uptiblue viable cell counting reagent 
(Uptima). a p= 0.60 compared with pcDNA/
GW-40/lacZ ; b p= 0.01 compared with 
pcDNA/GW-40/lacZ ; c p= 0.02 compared 
with pMYCNBMC Cancer 2009, 9:445 http://www.biomedcentral.com/1471-2407/9/445
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which contains the uORF of MYCNΔ1b mRNA, allowed the
production of a V5 epitope-tagged protein of approxi-
mately 15 kDa, whereas the transfection of p-uORF/Myc,
which contains the uORF of the full length MYCN tran-
script, did not (Fig. 3a). This 11.8 kDa new protein was
named MYCNOT: MYCN Overlap Transcript.
To validate the existence of endogenous MYCNOT, we
performed a Western blot analysis using a specifically
designed polyclonal antibody raised in rabbit against a N-
terminal epitope (NGAERSPQSPAGRRA) [anti-MYC-
NOT] of the hypothetical protein. The designed MYCNOT
antibody was able to detect in transfected SH-EP cells with
p-uORF/MYCNΔ1b the same protein detected with the V5
epitope antibody (Fig. 3b), The anti-MYCNOT antibody
was able to detect a ~12 kDa protein in foetal but not in
adult brain (Fig. 3c), thus confirming the existence of an
endogenous MYCNOT protein. An analysis of MYCNOT
sequence with BLAST and PROSITE software did not show
any sequence or motif homology.
Discussion
Because upstream ORF are known to influence protein
translation [23], we investigated the MYCN translation
from the full length MYCN  mRNA and the exon 1b-
spliced MYCNΔ1b mRNA. Only these two mRNAs are able
to translate the MYCN protein. More recently, in 2005,
van Bokhoven et al described a new exon 1a/2-spliced
mRNA able to translate a new protein named ΔMYCN [4].
In SH-EP cells, we demonstrated that both MYCN and
MYCNΔ1b were able to translate the MYCN protein, but
MYCN translation from MYCNΔ1b mRNA was much more
efficient. This difference may not be attributed to a differ-
ential stability of the two transcripts because they have the
same half-life of approximatively 15 minutes [2]. But, that
could be due to differences in the regulating activities of
uORFs in the two mRNAs. Because, the coding AUG is sev-
eral hundreds nucleotides after the stop codon of the
uORF in MYCN  mRNA compared to the overlapping
uORF in MYCNΔ1b transcript, we should have expected a
higher translation of MYCN protein from full length
mRNA due to reinitiation [6,23], but as already demon-
strated, this mRNA contains an Internal Ribosome Entry
Site (IRES) that could explain the higher initiation of
translation at the major AUG in MYCNΔ1b  mRNA
[5,24,25].
Upstream ORFs are usually known for their cis-acting
inhibitory activity on the translation of the major protein
[7,26-30]. To test this hypothesis, uAUG was mutated into
AUC. This mutation had no effect on MYCN translation
from  MYCNΔ1b  mRNA but significantly impacted the
translation from MYCN mRNA. Thus, MYCN uORFs have
different cis-regulatory activities in MYCN translation
depending on the alternative splicing of exon 1b. In our
conditions, the uORF of the MYCNΔ1b mRNA did not
affect MYCN translation. Alternatively, the uORF tran-
scribed from full length MYCN mRNA has cis-enhancing
activity on MYCN translation. To our knowledge, only
one team has shown that an uORF is able to augment the
translation of the HIV-1 Env protein from the HIV-1
mRNA [30]. Taken together, our results suggest the exist-
ence of a new level of MYCN regulation. One hypothesis
should be further explored: in cap-dependent conditions,
low-level MYCN would be produced from the full length
mRNA and this translation would be sustained by the
activity of the uORF whereas in IRES-dependent condi-
tions, high-level MYCN would be produced from exon
1b-spliced mRNA, independently of the uORF.
Numerous experiments have demonstrated important
ontogenic [31] and oncogenic [14] roles. The amplifica-
tion and overexpression of MYCN  primarily found in
25% of neuroblastomas [16] and in other tumours
Translation of uORF and existence of MYCNOT Figure 3
Translation of uORF and existence of MYCNOT. a) 
SH-EP cells were transfected with either p-uORF/MYCN (lane 
1) or p-uORF/MYCNΔ1b (lane 2). Western blot was conducted 
on 40 μg proteins, 48 hours after transfection with -upper 
panel: a monoclonal antibody against the V5 epitope (1:300) 
and -lower panel: the anti β-Actin antibody (1:10000). L: pro-
tein ladder; b) SH-EP cells were transfected with p-uORF/
MYCNΔ1b. Western blot was conducted on 40 μg protein, 48 
hours after transfection with -left panel: a monoclonal anti-
body against the V5 epitope (1:300) and -right panel: a poly-
clonal rabbit anti-NGAERSPQSPAGRRA peptide [anti-
MYCNOT] polyclonal antibody (1:100) L: protein ladder; c) 
Western blot analysis of 40 μg protein extracts from adult 
(lane 1) and foetal (lane 2) brain. Results obtained with -
upper panel: the anti-MYCNOT antibody (1:100) and -lower 
panel: the anti β-Actin antibody (1:10000).BMC Cancer 2009, 9:445 http://www.biomedcentral.com/1471-2407/9/445
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including medulloblastoma, retinoblastoma, small cell
lung cancer, glioblastoma and other embryonal tumours
[17] suggest the implication of MYCN dosage in cancer
development and aggressive expressivity.
Our results showed that, in transfected SH-EP neuroblast-
oma cells, high MYCN dosage obtained with MYCNΔ1b
mRNA translation induces a weak but significant antiap-
optotic effect after serum deprivation that was not
observed with low MYCN expression obtained with
MYCN mRNA. Our results do not fit the accepted pro-
apoptotic properties of MYCN: using a MYCN-inducible
SH-EP Tet21/N cell line, it has been demonstrated that
MYCN overexpression enhances either doxorubicin- or
platinum-induced apoptosis [19]. Using a similar
approach, Cui et al have shown that the transfection of
SH-EP cells with a pBabe-hygro/MYCN vector sensitises the
cells to TRAIL-triggered apoptosis[21]. But, as we did,
Jasty et al have reported a significant increase of cell viabil-
ity with high MYCN expression after 6 days of serum dep-
rivation [32]. These different results and ours suggest that
MYCN overexpression in SH-EP cells might have different
effects depending on the existence of an intrinsic (serum
deprivation) or extrinsic (TRAIL or drug-induced apopto-
sis) pathway-mediated apoptosis. Thus, MYCN dosage,
depending on translation of the alternatively exon 1b
splicing mRNA, enhances cell viability after intrinsic path-
way-mediated apoptosis.
As previously proposed, the uAUG codon located in exon
1a may initiate the translation of ΔMYCN, a new isoform
of the MYCN protein [4]. It has also been hypothesized,
but not proven at this time, that this uAUG is able to
translate a protein (GenBank: AAG40001.1) [5]. We now
demonstrated the existence of this 11.8 kDa protein and
named it MYCNOT: MYCN Overlap Transcript. Even if
uORFs appear to apply to as much as 50% of the transcrip-
tome [6,7,23], only few papers have reported their trans-
lation in in-vitro experiments using chimeric tag-fusion
proteins [23]. This is particularly true for the MYC gene, to
which MYCN is related, which presents several uORFs:
one uORF in exon 1 conducts to the translation of a pro-
tein of unknown function called MYCHEX1 [33]. To our
knowledge, only one team, using two-dimensional chro-
matography and mass spectrometry analysis, has been
able to prove the existence of eight proteins encoded by
uORFs in human K562 and HEK293 cell lines [34]. More-
over, these small proteins (< 20 kDa) were not subject to
rapid proteasome degradation suggesting functional activ-
ity [34]. The MYCNOT protein, which has no homology
with MYCN, other known proteins or protein motifs,
shares exon 1a-encoded amino acids with the putative
ΔMYCN previously described [4]. Because MYCNOT is
translated in foetal but not adult brain, we may hypothe-
size that it plays a role during neural development. Our
results need further analysis to determine the functions of
MYCNOT and might provide new insights into MYCN
regulation.
Conclusion
The MYCN gene is transcribed into two major mRNAs
which are differently translated. Higher levels of protein
were seen with MYCNΔ1b mRNA. Existence of an upstream
ORF was shown to have positive cis-regulatory activity on
translation from MYCN but not from MYCNΔ1b mRNA.
The high MYCN dosage obtained with MYCNΔ1b mRNA
translation induces, in transfected SH-EP neuroblastoma
cells, a weak but significant antiapoptotic effect after
serum deprivation that was not observed with low MYCN
expression.
Here, we show the translation of a new protein of
unknown function from the upstream AUG of MYCNΔ1b
mRNA.
In conclusion, further studies are now needed to explore
the exact relationship between alternative splicing of exon
1b, MYCN dosage, and the mechanism, either extrinsic or
intrinsic, underlying apoptosis.
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